Clinical trial · Interventional
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
NCT04348006CI-TRIAL-00066031MMwithdrawnPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No patients were enrolled in the study
Summary
Brief summary (as posted)
Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Newly Diagnosed Multiple Myeloma | Multiple Myeloma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bortezomib 3.5 MG | Drug | Bortezomib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Induction Therapy
- description
- Bortezomib will be administered as part of VCD or VRD protocols
- interventionNames
- Drug: Bortezomib 3.5 MG
Primary outcomes (2)
- measure
- Assessment the safety of Alvocade® therapy
- timeFrame
- During 6 months
- description
- Monitoring the rate of any adverse effect/event that will occur during the induction therapy
- measure
- Assessment the effecacy of Alvocade® therapy
- timeFrame
- At end of 6 months
- description
- Assessment of overall response rate (ORR) of treatment after completion of induction protocol
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions) * Age above 18 years old Exclusion Criteria: * Age below 18 years * Smoldering MM
References
Publications (0)
Data not yet available
No reference posted for this study.